Clinical Trial Update: Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating Palifermin (Kepivance) in patients undergoing unrelated donor allogeneic hematopoietic cell transplantation has completed …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma
• Leukemia
• Multiple Myeloma
• Myelodysplastic Syndromes
• Non-hodgkin Lymphoma

Drugs mentioned

• Kepivance (Palifermin)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Myelodysplastic Syndromes, Hodgkin's Lymphoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2025-06-05